Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
- UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals June 9, 2026
- BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap June 9, 2026
A New Frontier: Magnetic Nanoparticle Hyperthermia for Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxIn November 2025, Mayo Clinic in Rochester, Minnesota installed the first magnetic nanoparticle hyperthermia system in the United States for cancer research. The first patient was treated in December 2025, marking a major step toward bringing a long‑overlooked concept into the modern, heavily pretreated cancer landscape. Hyperthermia, the therapeutic use of heat, has been studied […]
Genomic Alterations and LuPSMA Outcomes in mCRPC: A Prognostic Insight
/in Retrospective studies/by MaxGenomic alterations like TP53, PTEN, and RB1 mutations are prevalent in metastatic castration-resistant prostate cancer (mCRPC), yet their impact on response to 177Lu-PSMA-617 (LuPSMA, Pluvicto) radioligand therapy remains underexplored. A recent retrospective study published in the Journal of Nuclear Medicine analyzed 72 mCRPC patients treated with at least one cycle of LuPSMA between October 2022 […]
FDA Abandons Two-Trial Standard: Implications for Drug Development
/in FDA approvals/by MaxThe FDA announced on February 18, 2026, that it will no longer require two pivotal clinical trials for new drug approvals, establishing a single-trial approach as the default standard. In a New England Journal of Medicine perspective, FDA leaders argued that the “two-trial dogma”, unchallenged since the 1960s, is obsolete given advances in biology, statistical […]
Ultrasound Nanobubbles Crack Prostate Cancer’s Collagen Fortress Improving Immunotherapy Penetration
/in Delivery, Immunotherapy, Preclinical Research/by MaxResearchers at Case Western Reserve University used tiny ultrasound-activated nanobubbles to dismantle the tough collagen walls that shield solid tumors from treatments. These “fortresses” made of stiff, crosslinked collagen block immune cells and drugs from reaching cancer cells deep inside, a major hurdle in fighting aggressive tumors like prostate cancer. The nanobubbles, filled with inert […]
SHR-4394: Phase 1/2 Trial Explores CDK4/6 Inhibition in Metastatic Prostate Cancer Combinations
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA promising Phase 1/2 clinical trial is investigating SHR-4394, a selective CDK4/6 inhibitor, combined with anti-tumor therapies such as rezvilutamide, HRS-5041, or tazemetostat in men with metastatic prostate cancer. CDK4/6 inhibitors like SHR-4394 block a key pathway that makes prostate cancer cells grow out of control. This pathway uses proteins called cyclin D, CDK4/6, and […]
BG-C0979: Pioneering Phase 1 Trial Targets ADAM9 in Advanced Solid Tumors, Including CRPC
/in Clinical Trial, Metastatic, Non-Metastatic, Phase 1, Phase 1/by MaxA first-in-human Phase 1 clinical trial is underway to evaluate BG-C0979, a novel antibody-drug conjugate (ADC) designed for adults with advanced solid tumors. This open-label study focuses on assessing the drug’s safety, tolerability, pharmacokinetics, and early signs of antitumor activity through dose escalation and potential expansion phases. BG-C0979 targets ADAM9, a disintegrin and metalloproteinase enzyme […]
Phase 1/2 ACRES Trial: Pioneering 225Ac-rhPSMA-10.1 for Post-Lutetium mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxThe ACRES trial represents a promising step forward in targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC), focusing on Actinium-225-labeled radiohybrid PSMA-10.1 (225Ac-rhPSMA-10.1) in patients who have largely progressed after Lutetium-177 PSMA therapy. This multi-site, open-label Phase 1/2 study addresses an urgent need in advanced prostate cancer, where effective post-Lu-PSMA options remain limited despite […]
EBNK-001: Pioneering Off-the-Shelf NK Cell Therapy for Solid Tumors
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxEBNK-001 represents a promising advancement in cancer immunotherapy as an “off-the-shelf” allogeneic natural killer (NK) cell product designed for multi-dose administration in patients with advanced solid tumors. Unlike autologous therapies that require individual patient cell harvesting and processing, EBNK-001 leverages healthy donor-derived NK cells, enabling immediate availability without lengthy manufacturing delays. This off-the-shelf approach addresses […]